Drug Combination Nanoparticles (DcNP)

Main developer(s)

Targeted & Long-acting drug Combination (TLC) Program, University of Washington

https://depts.washington.edu/tlcart/
Sponsor(s)

Unitaid
https://unitaid.org
Partnerships

Clinton Health Access Initiative
https://www.clintonhealthaccess.org/

Medicines Patent Pool
https://medicinespatentpool.org/
Technology information

**Type of technology**
Based on other organic particles, Aqueous drug particle suspension

**Administration route**
Subcutaneous, Intravenous

**Development state and regulatory approval**

**Active Pharmaceutical Ingredient (API)**
Dolutegravir, Tenofovir, Lamivudine

**Development Stage**
Pre-clinical

**Regulatory Approval**
Not provided
Description

A Targeted and long-acting Drug combination Nano-Particle (DcNP) platform that enables transformations of existing and new drug entities from short-acting daily doses to a long-acting drug combination for a maximum therapeutic effect through sustained viral suppression.

Technology highlight

TLC’s enabling DcNP technology has been validated to work with a number of current HIV drug combinations using clinics in both pediatric and adult populations. A number of these formulations have been evaluated in non-human primate models to provide both plasma and cell drug levels that persist for weeks after a single subcutaneous injection. This technology has been shown to bring together water soluble (such as tenofovir and lamivudine) and insoluble (such as lopinavir, ritonavir, atezanovir, and dolutegravir) drugs into an all-in-one long-acting injectable product. At least 4 formulations have been tested in NHP to have long-acting plasmakinetics for all drugs and are targeted to enhanced drug levels above plasma drug combinations in HIV host cells-PBMCs.
Technology main components

Drug API and common lipid excipients used in pharmaceutical formulations.

Information on the raw materials sourcing, availability and anticipated price

The existing HIV drug APIs can be sourced through WHO pre-qualified raw material suppliers.

Delivery device(s)

No delivery device
APIs compatibility profile

API desired features

Water-soluble molecules

Water-insoluble molecules

Small molecules
Tenofovir, Lamivudine, Dolutegravir, Lopinavir, Ritonavir, Atazanavir, Efavirenz

Additional solubility data
Not provided

Additional stability data
Not provided

API loading: Maximum drug quantity to be loaded
10-30 wt%

API co-administration
3-4 drugs
Scale-up and manufacturing prospects

Scale-up prospects

Good

Tentative equipment list for manufacturing

Spray-dryer; homogenization; size-reduction

Manufacturing

Injectable cGMP facilities

Specific analytical instrument required for characterization of formulation

Not provided
Excipients

Proprietary excipients used

No proprietary excipient used

Novel excipients or existing excipients at a concentration above Inactive Ingredients Database (IID) for the specified route of administration

No novel excipient or existing excipient used

Residual solvents used

No residual solvent used
Additional features

Other features of the technology

- Biodegradable
- Non-removable
- Room temperature storage
- At least 1 year shelf life

Release properties

Intracellular uptake and accessible by cellular enzymes to transform into active metabolites such as TFV-DP and 3TC-TP.

Injectability

Not provided

Safety

Not provided

Stability

Not provided

Storage conditions and cold-chain related features

No cold-chain needed
Potential application(s)

Therapeutic area(s)

- Type 2 diabetes
- HIV Treatment

Use of technology

Ease of administration

- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- Self-administered

Frequency of administration

Monthly, Once every 8 weeks

User acceptance

Potentially good

Targeted user group

Both male and female HIV+ needing chronic use of medication
Potential associated API(s)

Dolutegravir, Tenofovir, Lamivudine

Class(es)
Antiviral

Development stage
Pre-clinical

Clinical trial number(s)
Not provided

Foreseen/approved indication(s)
Treatment for people living with HIV

Foreseen user group
People living with HIV (Chronic HIV positive patients)

Foreseen duration between application(s)
1-3 months

Applications to Stringent Regulatory Authorities (SRA) / regulatory approvals
Not provided
Lopinavir, Ritonavir, Tenofovir

Class(es)
antiviral

Development stage
Pre-clinical

Clinical trial number(s)
Not provided

Foreseen/approved indication(s)
Treatment of HIV positive subjects to provide sustained viral suppression

Foreseen user group
Chronic HIV positive populations

Foreseen duration between application(s)
1-3 months

Applications to Stringent Regulatory Authorities (SRA) / regulatory approvals
Not provided
Drug Combination Nanoparticles for multiple drugs extended release
Expiry date: 2036-06-15
Multi-drug lipid nanoparticles that stably incorporate multiple small molecule drugs with divergent hydrophobic and water solubility characteristics and related methods of making and using the same. The disclosed compositions and methods provide for enhanced stability of lipid nanoparticle drug formulations that can reliably provide drugs addressing different mechanistic targets with prolonged presence in the body for more efficacious treatment and avoidance of single drug resistance.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Combination Nanoparticles for multiple drugs extended release</td>
<td>WO2016205384</td>
<td>Long-acting platform</td>
<td>The University Of Washington</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

**Patent status**

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low- middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>United States of America</td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td>China</td>
<td>World Intellectual Property Organization (WIPO)</td>
</tr>
</tbody>
</table>

Not in force

**MPP Licence(s)**

MPP/Uni Washington licence on Drug Combination Nanoparticles (DcNP) - HIV prevention/treatment

Combination pharmaceutical compositions including a combination of hydrophilic and hydrophobic therapeutic agents

Expiry date: 2040-01-10

The current invention is about a pharmaceutical formulation with a hydrophilic and hydrophobic drug along with a compatibilizer (lipid). The method of preparation is by dissolving all the components in suitable mixture of solvents, and then evaporating the solvent to get the powder form.

Patent status

- Granted
- Filed
- Not in force

MPP Licence(s)

MPP/Uni Washington licence on Drug Combination Nanoparticles (DcNP) - HIV prevention/treatment

Antiviral compositions that transform short-acting therapeutic agents into long-acting injectable forms that lasts for many weeks per administration
Expiry date: 2041-01-07
The present disclosure describes simple, stable, and scalable antiviral therapeutic agent compositions that transform short-acting antiviral (e.g., anti-HIV) therapeutic agents that would otherwise require daily short-acting oral administration into long-acting injectable forms that lasts for many weeks per administration. A mixture of water-soluble and water-insoluble antiviral therapeutic agents can be present in the long-acting and drug-combination composition.

Patent status/countries

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td></td>
<td>World Intellectual Property Organization (WIPO)</td>
</tr>
<tr>
<td>Not in force</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MPP Licence(s)

MPP/Uni Washington licence on Drug Combination Nanoparticles (DcNP) - HIV prevention/treatment

Tenofovir/Dolutegravir/Lamivudine (LAI candidate)

**Patent informations**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Emtricitabine and lamivudine compounds</td>
<td>CA2009637</td>
<td>Compound</td>
<td>Biochem Pharma Inc, Biochem International, Inc</td>
<td>No</td>
<td>Health Canada</td>
</tr>
</tbody>
</table>

**Patent status**

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Czechoslovakia (Defunct)</td>
<td>United States of America, Australia, Germany, Spain, Finland, Ireland, Portugal</td>
</tr>
<tr>
<td>Filed</td>
<td></td>
<td>Cyprus, Hungary, Japan, Latvia, New Zealand, Poland, Singapore, Slovenia, Slovakia</td>
</tr>
<tr>
<td>Not in force</td>
<td>Bosnia and Herzegovina, Yugoslavia/Serbia and Montenegro, China, Honduras, Soviet Union, South Africa, Botswana, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Sudan, Eswatini, Uganda, Zambia, Zimbabwe, Burkina Faso, Benin, Central African Republic, Congo, Côte d'Ivoire, Cameroon, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Chad, Togo, Malaysia, Philippines, Armenia, Kyrgyzstan, Tajikistan, Sri Lanka, Dominican Republic, Georgia, Uzbekistan, Mexico, Moldova, Republic of, Ukraine</td>
<td>Canada, Austria, Denmark, Greece, Hong Kong, Croatia, Israel, Korea, Republic of, Luxembourg, Netherlands, Norway, Belgium, Switzerland, France, United Kingdom, Italy, Liechtenstein, Sweden, Uruguay, Saudi Arabia</td>
</tr>
</tbody>
</table>
## Patent informations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Emtricitabine and lamivudine - process for preparing</td>
<td>WO9414802</td>
<td>Low, Low-middle and upper-middle</td>
<td>Belleau, Pierrette +Hf, Biochem Pharma Inc, Evans, Colleen, A, Jin, Haolun, Mansour, Tarek, Nguyen Ba, Nghe, Tse, Allan, Zacharie, Boulus</td>
<td>No</td>
<td>EPO (extended family)</td>
</tr>
</tbody>
</table>

## Patent status

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td>World Intellectual Property Organization (WIPO), Australia</td>
<td></td>
</tr>
<tr>
<td>Not in force</td>
<td>Canada, Austria, Germany, Denmark, Spain, Hungary, Japan, Portugal, Belgium, Switzerland, France, United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden</td>
<td></td>
</tr>
</tbody>
</table>
**Patent informations**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamivudine compound</td>
<td>WO9117159</td>
<td>Compound</td>
<td>Iaf Biochem International Inc</td>
<td>No</td>
<td>Health Canada</td>
</tr>
<tr>
<td>(-)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-y1)-(1H)-pyrimidin-2-one, its pharmaceutical acceptable derivatives, pharmaceutical formulations thereof, methods for its preparation and its use as an antiviral agent are described.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patent status**

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low- middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>United States of America</td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td>Bulgaria, Czechoslovakia (Defunct)</td>
<td>World Intellectual Property Organization (WIPO), Australia, Finland, Hungary, Japan, New Zealand, Poland, Romania, Singapore, Slovenia</td>
</tr>
<tr>
<td>Not in force</td>
<td>Bosnia and Herzegovina, Yugoslavia/Serbia and Montenegro, China, Morocco, Moldova, Republic of, Soviet Union, Tunisia, South Africa, Botswana, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Sudan, Eswatini, Uganda, Zambia, Zimbabwe, Burkina Faso, Benin, Central African Republic, Congo, Côte d’Ivoire, Cameroon, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Chad, Togo, Egypt, Ukraine</td>
<td>Canada, United Kingdom, Hong Kong, Croatia, Ireland, Israel, Korea, Republic of, Norway, Portugal, Slovakia, Taiwan, Province of China, Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, Greece, Italy, Liechtenstein, Luxembourg, Netherlands, Sweden</td>
</tr>
</tbody>
</table>
**Patent informations**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamivudine crystal forms</td>
<td>WO9221676</td>
<td></td>
<td></td>
<td>No</td>
<td>Health Canada, US FDA</td>
</tr>
</tbody>
</table>

**Expiry date:** 2012-06-02

(-)$i(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-one in crystalline form, in particular as needle-shaped or bipyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.

**Patent status**

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low- middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Czechoslovakia (Defunct)</td>
<td>Spain, United States of America</td>
</tr>
<tr>
<td>Filed</td>
<td>Bulgaria</td>
<td>Australia, Iceland, Singapore, World Intellectual Property Organization (WIPO)</td>
</tr>
<tr>
<td>Not in force</td>
<td>Mexico, Russian Federation, South Africa, Botswana, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Sudan, Eswatini, Uganda, Zambia, Zimbabwe, Burkina Faso, Benin, Central African Republic, Congo, Côte d'Ivoire, Cameroon, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Chad, Togo, Philippines, Ukraine, Pakistan, Georgia</td>
<td>Canada, United Kingdom, Austria, Germany, Denmark, Hong Kong, Ireland, Israel, Japan, Korea, Republic of, Norway, New Zealand, Portugal, Slovakia, Taiwan, Province of China, Belgium, Switzerland, France, Greece, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden</td>
</tr>
</tbody>
</table>
## Patent informations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir disoproxil compounds</td>
<td>WO9804569</td>
<td>Compound</td>
<td></td>
<td>No</td>
<td>Health Canada, US FDA, MPP Licence</td>
</tr>
</tbody>
</table>

## Patent status

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Japan, Luxembourg, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td>World Intellectual Property Organization (WIPO)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not in force</td>
<td>China, India</td>
<td>Canada, Austria, Australia, Germany, Denmark, Spain, Hong Kong, Korea, Republic of, Netherlands, New Zealand, Portugal, Taiwan, Province of China, United States of America, Belgium, Switzerland, Finland, France, Greece, Ireland, Italy, Liechtenstein, Monaco, Sweden, Chile, Singapore</td>
<td></td>
</tr>
</tbody>
</table>
### Patent information

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir disoproxil fumarate (TDF)</td>
<td>WO9905150</td>
<td>Compound</td>
<td>No</td>
<td>Health Canada, US FDA, MPP Licence</td>
<td></td>
</tr>
</tbody>
</table>

#### Patent status

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low- middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Japan</td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td>World Intellectual Property Organization (WIPO)</td>
<td></td>
</tr>
<tr>
<td>Not in force</td>
<td>Brazil, China, India, Mexico, Indonesia, Albania</td>
<td>Canada, United States of America, Austria, Australia, Germany, Denmark, Spain, Hong Kong, Korea, Republic of, New Zealand, Portugal, Singapore, Slovenia, Taiwan, Province of China, Belgium, Switzerland, Cyprus, Finland, France, United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden, Lithuania, Latvia, Romania</td>
</tr>
</tbody>
</table>
## Patent informations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir alafenamide fumarate (TAF)</td>
<td>WO0208241</td>
<td>Compound</td>
<td></td>
<td>No</td>
<td>Health Canada, US FDA</td>
</tr>
</tbody>
</table>

## Patent status

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low- middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Bulgaria, Mexico, Turkey, Ukraine, South Africa, Russian Federation, Burkina Faso, Benin, Central African Republic, Congo, Côte d'Ivoire, Cameroon, Gabon, Guinea, Equatorial Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Senegal, Chad, Togo, Albania, India, Viet Nam, North Macedonia, Congo, democratic Republic of the, Ethiopia, Fiji, Grenada, Guyana, Kiribati, Solomon Islands, Tuvalu, Saint Lucia</td>
<td>Australia, Denmark, Estonia, Hong Kong, Croatia, Hungary, Israel, Iceland, Japan, Korea, Republic of, Poland, Portugal, Slovenia, United States of America, Belgium, Switzerland, Cyprus, Germany, Finland, France, Greece, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden, Lithuania, Romania, Latvia, Brunei Darussalam, Czechia, Anguilla, Bermuda, Falkland Islands (Malvinas), Montserrat, Seychelles, Virgin Islands (British), Saint Helena, Ascension and Tristan da Cunha, Singapore, Cayman Islands, Jersey, Gibraltar, Guernsey</td>
</tr>
<tr>
<td>Filed</td>
<td>Haiti, Jamaica, Nepal</td>
<td>Norway, World Intellectual Property Organization (WIPO), Turks and Caicos Islands</td>
</tr>
<tr>
<td>Not in force</td>
<td>China, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Mozambique, Sudan, Sierra Leone, Swaziland, Tanzania, United Republic of, Uganda, Zimbabwe, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Republic of, Tajikistan, Turkmenistan, Indonesia, Brazil</td>
<td>Canada, Spain, New Zealand, Austria, United Kingdom, Ireland</td>
</tr>
</tbody>
</table>
### Patent information

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dolutegravir and Cabotegravir</td>
<td>WO2006116764</td>
<td>Compound</td>
<td>Glaxosmithkline Llc, Johns Brian Alvin, Kawasui Takashi, Shionogi &amp; Co., Ltd,</td>
<td>Yes</td>
<td>US FDA, Health Canada</td>
</tr>
<tr>
<td>compounds</td>
<td></td>
<td></td>
<td>Taishi Teruhiko, Taoda Yoshiyuki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expiry date: 2026-04-28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WO2006116764 discloses compound</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTG as Example Y-3 on page 116. DTG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>is specifically claimed in claim 32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>on page 267. CAB is disclosed as</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Example Z-1 on page 128 and claim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31 on p 261</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Patent status

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Brazil, China, Morocco, Mexico,</td>
<td>United States of America, Australia, Canada, Cyprus, Denmark, Spain, Hong</td>
</tr>
<tr>
<td></td>
<td>Philippines, Ukraine, Viet Nam,</td>
<td>Kong, Israel, Japan, Korea, Republic of, Luxembourg, Norway, New Zealand,</td>
</tr>
<tr>
<td></td>
<td>South Africa, Bulgaria, Turkey,</td>
<td>Portugal, Slovenia, Taiwan, Province of China, Austria, Belgium, Switzerland,</td>
</tr>
<tr>
<td></td>
<td>Armenia, Azerbaijan, Belarus,</td>
<td>Czechia, Germany, Estonia, Finland, France, United Kingdom, Greece, Hungary,</td>
</tr>
<tr>
<td></td>
<td>Kyrgyzstan, Kazakhstan, Moldova,</td>
<td>Ireland, Iceland, Italy, Liechtenstein, Lithuania, Latvia, Monaco, Netherlands,</td>
</tr>
<tr>
<td></td>
<td>Republic of, Russian Federation,</td>
<td>Poland, Romania, Sweden, Slovakia, Trinidad and Tobago, Singapore</td>
</tr>
<tr>
<td></td>
<td>Tajikistan, Turkmenistan,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colombia, Indonesia, Malaysia,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Algeria</td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td>Nigeria, Egypt</td>
<td>World Intellectual Property Organization (WIPO)</td>
</tr>
<tr>
<td>Not in force</td>
<td>India</td>
<td></td>
</tr>
</tbody>
</table>

### MPP Licence(s)

**MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations**

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

**MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY**

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/
**Patent informations**

|------------------------------------------|-----------------------|------------|---------------|------------------|--------------|

**Patent status**

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low- middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Costa Rica, Morocco, Moldova, Republic of, Mexico, Peru, Botswana, Ghana, Gambia (the), Kenya, Liberia, Lesotho, Malawi, Mozambique, Namibia, Rwanda, Sudan, Sierra Leone, Eswatini, Tanzania, United Republic of, Uganda, Zambia, Zimbabwe, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Russian Federation, Tajikistan, Turkmenistan, Viet Nam, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Indonesia, Philippines, South Africa, Ukraine, Brazil, El Salvador, Montenegro, Serbia, Turkey, Bulgaria, North Macedonia, Albania, Bosnia and Herzegovina</td>
<td>United States of America, Australia, Chile, Hong Kong, Israel, Japan, Korea, Republic of, New Zealand, Taiwan, Province of China, Uruguay, Denmark, Slovenia, Panama, Croatia, Lithuania, San Marino, Spain, Poland, Portugal, Cyprus, Hungary, Bahamas, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Czechia, Estonia, Slovakia, Iceland, Malta, Norway, Romania, Latvia</td>
</tr>
<tr>
<td>Filed</td>
<td>Argentina, China, Ecuador, India, Bolivia (Plurinational State of), Paraguay, Thailand, Venezuela (Bolivarian Republic of), Egypt</td>
<td>World Intellectual Property Organization (WIPO), Canada, Singapore, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates</td>
</tr>
<tr>
<td>Not in force</td>
<td>Colombia, Pakistan</td>
<td></td>
</tr>
</tbody>
</table>
## Patent informations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TAF manufacturing process</td>
<td>WO2013052094</td>
<td>Low, Low-middle and upper-middle</td>
<td></td>
<td>No</td>
<td>MPP license</td>
</tr>
</tbody>
</table>


## Patent status

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>China, Colombia, Mexico, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Russian Federation, Tajikistan, Turkmenistan, Albania, North Macedonia, Serbia, Turkey, Bosnia and Herzegovina, Montenegro</td>
<td>Australia, Japan, Korea, Republic of, United States of America, Austria, Belgium, Switzerland, Cyprus, Czechia, Germany, Estonia, Spain, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Italy, Liechtenstein, Latvia, Monaco, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, San Marino, New Zealand, Israel</td>
</tr>
<tr>
<td>Filed</td>
<td>Argentina</td>
<td>Canada, Hong Kong, Taiwan, Province of China, World Intellectual Property Organization (WIPO)</td>
</tr>
</tbody>
</table>

| Not in force            | Costa Rica, Peru, Bulgaria, Brazil, Ecuador | Chile, Uruguay, Denmark, Finland, Iceland, Lithuania, Luxembourg |
Patent information

Patent description: Dolutegravir/Cabotegravir intermediates production processes & Intermediates

Expiry date: 2029-12-09

Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P 1 P3, R3 and Rx are as described herein.

Patent status

- **Licence with MPP**: Yes
- **Patent source**: MPP Licence

MPP Licence(s)

- **MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations**
  
  [https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/](https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/)

- **MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY**
  
**Patent informations**

**Patent description**

Dolutegravir salts, their crystals & process  
Expiry date: 2029-12-08  
A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.

**Representative patent**

WO2010068253

**Categories**

Glaxosmithkline Llc,  
Johns, Brian, Alvin,  
Shionogi & Co., Ltd,  
Taoda, Yoshiyuki,  
Yoshida, Hiroshi

**Patent holder**

**Licence with MPP**

Yes

**Patent source**

US FDA

**Patent status**

**Patent status/countries**

Granted

Low, Low- middle and upper-middle  
China, Mexico, Russian Federation, Indonesia  
High income  
United States of America, Australia, Canada, Switzerland, Germany, Spain, France, United Kingdom, Ireland, Italy, Liechtenstein, Japan, Korea, Republic of, Singapore, Taiwan, Province of China

Filed

Brazil, India  
World Intellectual Property Organization (WIPO), Hong Kong

Not in force

Bulgaria, North Macedonia, Turkey  
Austria, Belgium, Cyprus, Czechia, Denmark, Estonia, Finland, Greece, Croatia, Hungary, Iceland, Lithuania, Luxembourg, Latvia, Monaco, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, San Marino

**MPP Licence(s)**

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/
Patent informations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabotegravir prodrugs &amp; Cabotegravir and Dolutegravir intermediates and processes</td>
<td>WO2010011814</td>
<td>Low, Low-middle and upper-middle</td>
<td>Glaxosmithkline Llc, Shionogi &amp; Co., Ltd, Viiv Healthcare Company</td>
<td>Yes</td>
<td>MPP Licence</td>
</tr>
</tbody>
</table>

Patent status

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>China, India</td>
<td>Belgium, Germany, France, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Liechtenstein, Spain, Portugal, Japan, Korea, Republic of, Singapore, United States of America</td>
</tr>
<tr>
<td>Filed</td>
<td>World Intellectual Property Organization (WIPO)</td>
<td></td>
</tr>
<tr>
<td>Not in force</td>
<td>Turkey, Bulgaria, North Macedonia, Bosnia and Herzegovina, Albania, Serbia</td>
<td>Luxembourg, Austria, Greece, Denmark, Monaco, Ireland, Finland, Cyprus, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia</td>
</tr>
</tbody>
</table>

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/
The present disclosure relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations may be useful in the inhibition of HIV-1 or potentially the inhibition of HIV replication, or for the prevention and/or treatment of infection by HIV, or in the treatment of AIDS and/or ARC.

**Patent status**

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low-middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Turkmenistan, Belarus, Tajikistan, Russian Federation, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Mexico</td>
<td>Canada, Australia, Israel</td>
</tr>
<tr>
<td>Filed</td>
<td>Turkey, Bulgaria, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia</td>
<td>United States of America, Singapore, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia</td>
</tr>
<tr>
<td>Not in force</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MPP Licence(s)**

**MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations**

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

**MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY**

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/
**Patent informations**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dolutegravir or cabotegravir in combination with ABC, 3TC or RPV</td>
<td>WO2011094150</td>
<td></td>
<td></td>
<td>Yes</td>
<td>MPP license</td>
</tr>
</tbody>
</table>

**Patent status**

<table>
<thead>
<tr>
<th>Patent status/countries</th>
<th>Low, Low- middle and upper-middle</th>
<th>High income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>Indonesia, Viet Nam, Philippines</td>
<td>Hong Kong, Oman, United Arab Emirates, World Intellectual Property Organization (WIPO), Bahrain</td>
</tr>
<tr>
<td>Filed</td>
<td>Dominican Republic, Algeria, Egypt, Thailand, Malaysia, Brazil, Tajikistan, Belarus, Russian Federation, Azerbaijan, Moldova, Republic of, Turkmenistan, Armenia, Kyrgyzstan, Kazakhstan</td>
<td></td>
</tr>
<tr>
<td>Not in force</td>
<td>Costa Rica, Ecuador, Libya</td>
<td></td>
</tr>
</tbody>
</table>

**MPP Licence(s)**

- **MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations**
  
  [https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/](https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/)

- **MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY**
  
Supporting material
The concept of nanomedicine is not new. For instance, some nanocrystals and colloidal drug molecules are marketed that improve pharmacokinetic characteristics of single-agent therapeutics. For the past two decades, the number of research publications on single-agent nanoformulations has grown exponentially. However, formulations advancing to pre-clinical and clinical evaluations that lead to therapeutic products has been limited. Chronic diseases such as cancer and HIV/AIDS require drug combinations, not single agents, for durable therapeutic responses. Therefore, development and clinical translation of drug combination nanoformulations could play a significant role in improving human health. Successful translation of promising concepts into pre-clinical and clinical studies requires early considerations of the physical compatibility, pharmacological synergy, as well as pharmaceutical characteristics (e.g. stability, scalability and pharmacokinetics). With this approach and robust manufacturing processes in place, some drug-combination nanoparticles have progressed to non-human primate and human studies. In this article, we discuss the rationale and role of drug-combination nanoparticles, the pre-clinical and clinical research progress made to date and the key challenges for successful clinical translation. Finally, we offer insight to accelerate clinical translation through leveraging robust nanoplatform technologies to enable implementation of personalised and precision medicine.

Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
Existing oral antiretroviral (ARV) agents have been shown in human studies to exhibit limited lymph node penetration and lymphatic drug insufficiency. As lymph nodes are a reservoir of HIV, it is critical to deliver and sustain effective levels of ARV combinations in these tissues. To overcome lymph node drug insufficiency of oral combination ARV therapy (cART), we developed and reported a long-acting and lymphocyte-targeting injectable that contains three ARVs—hydrophobic lopinavir (LPV) and ritonavir (RTV), and hydrophilic tenofovir (TFV)—stabilized by lipid excipients in a nanosuspension. A single subcutaneous (SC) injection of this first-generation formulation of drug combination nanoparticles (DcNPs), named TLC-ART101, provided persistent ARV levels in macaque lymph node mononuclear cells (LNMCs) for at least 1 week, and in peripheral blood mononuclear cells (PBMCs) and plasma for at least 2 weeks, demonstrating long-acting pharmacokinetics for all three drugs. In addition, the lymphocyte-targeting properties of this formulation were demonstrated by the consistently higher intracellular drug concentrations in LNMCs and PBMCs versus those in plasma. To provide insights into the complex mechanisms of absorption and disposition of TLC-ART101, we constructed novel mechanism-based pharmacokinetic (MBPK) models. Based upon plasma PK data obtained after single administration of TLC-ART101 (DcNPs) and a solution formulation of free triple-ARVs, the models feature uptake from the SC injection site that respectively routes free and nanoparticle-associated ARVs via the blood vasculature and lymphatics, and their eventual distribution into and clearance from the systemic circulation. The models provided simultaneous description of the complex long-acting plasma and lymphatic PK profiles for all three ARVs in TLC-ART101. The long-acting PK characteristics of the three drugs in TLC-ART101 were likely due to a combination of mechanisms including: (1) DcNPs undergoing preferential lymphatic uptake from the subcutaneous space, (2) retention in nodes during lymphatic first-pass, (3) subsequent slow release of ARVs into blood circulation, and (4) limited extravasation of DcNP-associated ARVs that resulted in longer persistence in the circulation.

Keywords: Mechanism-based pharmacokinetic modeling; Long-acting; Antiretrovirals; HIV drug combination treatment; Lymphatic targeted drug delivery; Lymphatic drug insufficiency


Early diagnosis along with new drugs targeted to cancer receptors and immunocheckpoints have improved breast cancer survival. However, full remission remains elusive for metastatic breast cancer due to dose-limiting toxicities of heavily used, highly potent drug combinations such as
gemcitabine and paclitaxel. Therefore, novel strategies that lower the effective dose and improve safety margins could enhance the effect of these drug combinations. To this end, we developed and evaluated a novel drug combination of gemcitabine and paclitaxel (GT). Leveraging a simple and scalable drug-combination nanoparticle platform (DcNP), we successfully prepared an injectable GT combination in DcNP (GT DcNP). Compared to a Cremophor EL/ethanol assisted drug suspension in buffer (CrEL), GT DcNP exhibits about 56-fold and 8.6-fold increases in plasma drug exposure (area under the curve, AUC) and apparent half-life of gemcitabine respectively, and a 2.9-fold increase of AUC for paclitaxel. Using 4T1 as a syngeneic model for breast cancer metastasis, we found that a single GT (20/2 mg/kg) dose in DcNP nearly eliminated colonization in the lungs. This effect was not achievable by a CrEL drug combination at a 5-fold higher dose (i.e., 100/10 mg/kg GT). A dose-response study indicates that GT DcNP provided a therapeutic index of ~15.8. Collectively, these data suggest that GT DcNP could be effective against advancing metastatic breast cancer with a margin of safety. As the DcNP formulation is intentionally designed to be simple, scalable, and long-acting, it may be suitable for clinical development to find effective treatment against metastatic breast cancer.

Objective:
To characterize a drug-combination nanoparticle (DcNP) containing water-insoluble lopinavir (LPV) and efavirenz (EFV), and water-soluble tenofovir (TFV), for its potential as a long-acting combination HIV treatment.

Design:
Three HIV drugs (LPV, EFV, TFV) with well established efficacy and safety were coformulated into a single DcNP suspension. Two macaques were administered one subcutaneous injection and drug concentrations in plasma and mononuclear cells (in peripheral blood and lymph nodes) were analyzed over 2 weeks. Pharmacokinetic parameters and cell-to-plasma relationships of LPV, EFV, and TFV were determined.

Koehn, Josefina; Iwamoto, Jennifer F.a; Kraft, John C.a; McConnachie, Lisa A.a; Collier, Ann C.b,c; Ho, Rodney J.Y.a,c,d

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates

AIDS: November 13, 2018 - Volume 32 - Issue 17 - p 2463-2467
doi: 10.1097/QAD.0000000000001969
Results:

This three-in-one nanoformulation provided extended concentrations of all drugs in lymph node cells that were 57- to 228-fold higher than those in plasma. Levels of all three drugs in peripheral blood mononuclear cells persisted for 2 weeks at levels equal to or higher than those in plasma.

Conclusion:

With long-acting characteristics and higher drug penetration/persistence in cells, this three-in-one DcNP may enhance therapeutic efficacy of these well studied HIV drugs due to colocalization and targeting of this three-drug combination to HIV host cells.

Yu Gao, John C. Kraft, Danni Yu, Rodney J.Y. Ho,

Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy,

European Journal of Pharmaceutics and Biopharmaceutics,

Volume 138, 2019, Pages 75-91, ISSN 0939-6411,

https://doi.org/10.1016/j.ejpb.2018.04.014.

Combination antiretroviral therapy (cART) given orally has transformed HIV from a terminal illness to a manageable chronic disease. Yet despite the recent development of newer and more potent drugs for cART and suppression of virus in blood to undetectable levels, residual virus remains in tissues. Upon stopping cART, virus rebounds and progresses to AIDS. Current oral cART regimens have several drawbacks including (1) challenges in patient adherence due to pill fatigue or side-effects, (2) the requirement of life-long daily drug intake, and (3) limited penetration and retention in cells within lymph nodes. Appropriately designed injectable nano-drug combinations that are long-acting and retained in HIV susceptible cells within lymph nodes may address these challenges. While a number of nanomaterials have been investigated for delivery of HIV drugs and drug combinations, key challenges involve developing and scaling delivery systems that provide a drug combination targeted to HIV host cells and tissues where residual virus persists. With validation of the drug-insufficiency hypothesis in lymph nodes, progress has been made in the development of drug combination nanoparticles that are long-acting and targeted to lymph nodes and cells. Unique drug combination nanoparticles (DcNPs) composed of three HIV drugs—lopinavir, ritonavir, and tenofovir—have been shown to provide enhanced drug levels in lymph nodes; and elevated drug-combination levels in HIV-host cells in the blood and plasma for two weeks. This review summarizes the progress in the development of nanoparticle-based drug delivery systems for HIV therapy. It discusses how injectable nanocarriers may be designed to enable delivery of drug combinations that are long-lasting and target-selective in physiological contexts (in vivo) to provide safe and effective use. Consistent drug combination exposure in the
sites of residual HIV in tissues and cells may overcome drug insufficiency observed in patients on oral cART.

Keywords: Nanomedicine; Long-acting; Targeted; Drug combination; HIV/AIDS


Purpose

To develop drug-combination nanoparticles (DcNPs) composed of hydrophilic gemcitabine (G) and hydrophobic paclitaxel (T) and deliver both drugs to metastatic cancer cells.

Methods

GT DcNPs were evaluated based on particle size and drug association efficiency (AE%). The effect of DcNP on GT plasma time-course and tissue distribution was characterized in mice and a pharmacokinetic model was developed. A GT distribution study into cancer nodules (derived from 4 T1 cells) was performed.

Results

An optimized GT DcNP composition (d = 59.2 nm ±9.2 nm) was found to be suitable for IV formulation. Plasma exposure of G and T were enhanced 61-fold and 3.8-fold when given in DcNP form compared to the conventional formulation, respectively. Mechanism based pharmacokinetic modeling and simulation show that both G and T remain highly associated to DcNPs in vivo (G: 98%, T:75%). GT DcNPs have minimal distribution to healthy organs with selective distribution and retention in tumor burdened tissue. Tumor bearing lungs had a 5-fold higher tissue-to-plasma ratio of gemcitabine in GT DcNPs compared to healthy lungs.
Conclusions

DcNPs can deliver hydrophilic G and hydrophobic T together to cancer nodules and produce long acting exposure, likely due to stable GT association to DcNPs in vivo.

Kraft, John C.a; McConnachie, Lisa A.a; Koehn, Josefina; Kinman, Lorena; Collins, Carola; Shen, Danny D.a; Collier, Ann C.b,c; Ho, Rodney J.Y.a,c,d Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma, AIDS: March 27, 2017 - Volume 31 - Issue 6 - p 765-770 doi: 10.1097/QAD.0000000000001405

Objective:

The aim of the present study was to determine whether a combination of anti-HIV drugs – tenofovir (TFV), lopinavir (LPV) and ritonavir (RTV) – in a lipid-stabilized nanosuspension (called TLC-ART101) could enhance and sustain intracellular drug levels and exposures in lymph node and blood cells above those in plasma.

Design:

Four macaques were given a single dose of TLC-ART101 subcutaneously. Drug concentrations in plasma and mononuclear cells of the blood (PBMCs) and lymph nodes (LNMCs) were analysed using a validated combination LC-MS/MS assay.

Results:

For the two active drugs (TFV, LPV), plasma and PBMC intracellular drug levels persisted for over 2 weeks; PBMC drug exposures were three- to four-fold higher than those in plasma. Apparent terminal half-lives (t1/2) of TFV and LPV were 65.3 and 476.9 h in plasma, and 169.1 and 151.2 h in PBMCs. At 24 and 192 h, TFV and LPV drug levels in LNMCs were up to 79-fold higher than those in PBMCs. Analysis of PBMC intracellular TFV and its active metabolite TFV-diphosphate (TFV-DP) indicated that intracellular exposures of total TFV and TFV-DP were markedly higher and persisted longer than in humans and macaques dosed with oral TFV prodrugs, tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).
Conclusions:

A simple, scalable three-drug combination, lipid-stabilized nanosuspension exhibited persistent drug levels in cells of lymph nodes and the blood (HIV host cells) and in plasma. With appropriate dose adjustment, TLC-ART101 may be a useful HIV treatment with a potential to impact residual virus in lymph nodes.


The distributed network of lymph vessels and nodes in the body, with its complex architecture and physiology, presents a major challenge for whole-body lymphatic-targeted drug delivery. To gather physiological and pathological information of the lymphatics, near-infrared (NIR) fluorescence imaging of NIR fluorophores is used in clinical practice due to its tissue-penetrating optical radiation (700–900 nm) that safely provides real-time high-resolution in vivo images. However, indocyanine green (ICG), a common clinical NIR fluorophore, is unstable in aqueous environments and under light exposure, and its poor lymphatic distribution and retention limits its use as a NIR lymphatic tracer. To address this, we investigated in mice the distribution pathways of a novel nanoparticle formulation that stabilises ICG and is optimised for lymphatic drug delivery. From the subcutaneous space, ICG particles provided selective lymphatic uptake, lymph vessel and node retention, and extensive first-pass lymphatic distribution of ICG, enabling 0.2 mm and 5–10 cell resolution of lymph vessels, and high signal-to-background ratios for lymphatic vessel and node networks. Soluble (free) ICG readily dissipated from lymph vessels local to the injection site and absorbed into the blood. These unique characteristics of ICG particles could enable mechanistic studies of the lymphatics and diagnosis of lymphatic abnormalities.

Drug-combination nanoparticles (DcNP) is a nano-formulation of multiple HIV drugs in one injectable. DcNP demonstrated long-acting pharmacokinetics (PK) for all drugs in the blood and lymphatic system of nonhuman primates (NHP). Long-acting is due to stably circulating DcNP and a depot in the lymphatic system during subcutaneous absorption. Because the PK of each drug in DcNP evolves through two species, i.e., drugs that dissociate from DcNP and drugs retained in DcNP (Part 2, presented separately), we describe here a physiologically based PK model of the nanoparticle-free drugs featuring the role of the lymphatic system. The free drug model was built using subcutaneous injections of suspended lopinavir-ritonavir-tenofovir in NHP and validated by external experiments. The model, for the first time, introduces the lymphatic network as part of a whole-body PBPK system and singles out major lymphatic regions: cervical, axillary, hilar, mesenteric, and inguinal nodes. Although the scope of the free-drug modeling was to support the construction of the nanoparticle model (Part 2), such a detailed/regionalized description of the lymphatic system and mononuclear cells represent an unprecedented level of prediction that renders the free drug model extendible to other small-drug molecules targeting the lymphatic system at both the regional and cellular level.

Additional documents

- UW Program on Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)

Useful links

- TLC-ART website
- MPP and UW sign a licence for an investigational LA injectable drug combination candidate for HIV
Access principles

Collaborate for development

Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology.

Not provided

Share technical information for match-making assessment

Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit.

Not provided

Work with MPP to expand access in LMICs

In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing.

Not provided
Comment & Information
TLD nanoparticle

None